This study is looking at how a special imaging scan, called rhPSMA-7.3 PET/CT, can help doctors treat men with high-risk prostate cancer. You would receive a dose of rhPSMA-7.3 (18F) through an IV, followed by a PET scan. This scan helps doctors find out if the cancer has spread. The main goal is to see if this scan changes how doctors plan your treatment, specifically if it leads to "upstaging" (meaning the cancer is found to be more advanced than initially thought). This study is for men aged 18 or older who have been diagnosed with high-risk prostate cancer. The study is currently unclear on its recruitment status and plans to enroll 113 participants.

Study design

This is a Phase 3b study involving one group of participants. It is designed to test a diagnostic imaging method in men with high-risk prostate cancer.

What's involved

You would have a rhPSMA-7.3 PET scan after your regular imaging tests. Your doctor will discuss the scan results with you within 7 days, and your treatment plan will be decided within 45 days.

Compensation

Not stated in the trial record.

Follow-up

The study will measure prostate cancer upstaging at 15 months after the imaging.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.